TREM2-APOE microglial state switching across AD, ALS, and PD
🧪 Overview
Shared mechanism across AD, ALS, PD: TREM2-APOE signaling shifts microglia into a disease-associated state that can clear debris but also amplify inflammatory injury. AD genetics implicate TREM2; ALS data connect TREM2 to TDP-43 neuroprotection; and PD microglia share the same damage-response programs around alpha-synuclein stress.
Falsifiable prediction: A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate clearance in AD amyloid, TDP-43 ALS, and alpha-synuclein PD cultures while reducing IL1B/TNFA induction by at least 20%.
Proposed experiment: Differentiate isogenic human microglia with TREM2 knockout, rescue, and biased agonist treatment; co-culture with amyloid/tau, TDP-43, and alpha-synuclein neuron models; assay phagocytosis, APOE-state markers, cytokines, complement deposition, and neuronal survival.
Cross-disease confidence rationale: Human AD genetics plus ALS TDP-43 microglial neuroprotection and broad DAM literature.
Internal SciDEX support: SciDEX support query found 313 matching hypotheses across 8 disease labels, including 313 with debate_count > 0.
🧬 Mechanism
Auto-built from this analysis's top knowledge-graph edges.
graph TD
TREM2_R47H_variant["TREM2 R47H variant"] -->|increases risk| Ad["Ad"]
TREM2["TREM2"] -->|cross disease mech| AD["AD"]
TREM2_1["TREM2"] -->|cross disease mech| ALS["ALS"]
TREM2_2["TREM2"] -->|cross disease mech| PD["PD"]
h_cross_synth_trem2_apoe_["h-cross-synth-trem2-apoe-microglia"] -->|proposes shared me| TREM2_3["TREM2"]
style TREM2_R47H_variant fill:#ce93d8,stroke:#333,color:#000
style Ad fill:#ef5350,stroke:#333,color:#000
style TREM2 fill:#4fc3f7,stroke:#333,color:#000
style AD fill:#ef5350,stroke:#333,color:#000
style TREM2_1 fill:#4fc3f7,stroke:#333,color:#000
style ALS fill:#ef5350,stroke:#333,color:#000
style TREM2_2 fill:#4fc3f7,stroke:#333,color:#000
style PD fill:#ef5350,stroke:#333,color:#000
style h_cross_synth_trem2_apoe_ fill:#4fc3f7,stroke:#333,color:#000
style TREM2_3 fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
🏥 Translation
🧬 3D Protein Structure — TREM2
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate clearance in AD amyloid, TDP-43 ALS, and alpha-synuclein PD cultures while reducing I | If this mechanism is real, then A biased TREM2 agonist that enhances phagocytosis without excessive NF-kB/AP-1 activation should improve aggregate clearance in | — no observation — | pending | 0.80 |
▸Metadatasource: v1_phase_c_backfill · origin_type: cross_disease_synthesis
| source | v1_phase_c_backfill |
| origin_type | cross_disease_synthesis |
| _schema_version | 1 |